TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
1-Year Est. Return
23.66%
1 Year Est. Return
+23.66%
AUM
$733M
AUM Growth
-$290M
(-28%)
Holding
38
Top Sells
| 1 | +$19.6M | |
| 2 | +$8.71M | |
| 3 | +$1.08M | |
| 4 |
RAPT Therapeutics
RAPT
|
+$55K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
THRD
26
DELISTED
Third Harmonic Bio
THRD
| $8.69M | 1.19% |
2,505,424
|
|
||
|
SLN
27
Silence Therapeutics
SLN
$311M
| $8.55M | 1.17% |
3,033,560
|
|
||
28
Adverum Biotechnologies
ADVM
$95.7M
| $7.85M | 1.07% |
1,796,482
|
|
||
29
VistaGen Therapeutics
VTGN
$124M
| $6.69M | 0.91% |
2,676,580
|
|
||
|
JBIO
30
Jade Biosciences
JBIO
$450M
| $5.62M | 0.77% |
64,023
|
|
||
31
Entrada Therapeutics
TRDA
$235M
| $5.29M | 0.72% |
584,955
|
|
||
|
MBX
32
MBX Biosciences
MBX
$616M
| $4.8M | 0.65% |
650,000
|
|
||
33
Avalo Therapeutics
AVTX
$249M
| $3.87M | 0.53% |
483,000
|
|
||
34
Kodiak Sciences
KOD
$788M
| $3.21M | 0.44% |
1,145,538
|
|
||
35
Nektar Therapeutics
NKTR
$1.05B
| $2.72M | 0.37% |
266,667
|
|
||
36
Ventyx Biosciences
VTYX
$285M
| $364K | 0.05% |
316,195
|
|
||
37
Cabaletta Bio
CABA
$263M
| $120K | 0.02% |
86,795
|
|
||
38
Keros Therapeutics
KROS
$418M
| – | – |
-550,000
|
|